Associated Genetic Biomarkers
Insulin receptor substrate 2 (IRS2) is a gene that encodes a protein of the same name that functions in regulating the effects of insulin-like growth factor 1 and insulin by mediating signaling between receptor tyrosine kinases and other associated proteins. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame insertions are observed in cancers such as esophageal cancer, intestinal cancer, and stomach cancer.
IRS2 is altered in 2.87% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in IRS2 are IRS2 Mutation (2.09%), IRS2 Amplification (0.61%), IRS2 Loss (0.14%), IRS2 A701dup (0.07%), and IRS2 P1036del (0.05%) .
IRS2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains IRS2 status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with IRS2 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is IRS2 Mutation (somatic) .
Capivasertib and olaparib are the most frequent therapies in trials with IRS2 as an inclusion criteria .
Significance of IRS2 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.